logo
Pleasing Signs As A Number Of Insiders Buy Finward Bancorp Stock

Pleasing Signs As A Number Of Insiders Buy Finward Bancorp Stock

Yahoo12-02-2025
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Finward Bancorp's (NASDAQ:FNWD) case, it's fantastic news for shareholders.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
Check out our latest analysis for Finward Bancorp
Notably, that recent purchase by Carolyn Burke is the biggest insider purchase of Finward Bancorp shares that we've seen in the last year. That means that even when the share price was higher than US$26.38 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
Over the last year, we can see that insiders have bought 4.06k shares worth US$113k. But they sold 738.70 shares for US$21k. In the last twelve months there was more buying than selling by Finward Bancorp insiders. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Finward Bancorp is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
It's good to see that Finward Bancorp insiders have made notable investments in the company's shares. Overall, three insiders shelled out US$103k for shares in the company -- and none sold. That shows some optimism about the company's future.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 13% of Finward Bancorp shares, worth about US$15m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
It is good to see recent purchasing. And the longer term insider transactions also give us confidence. Given that insiders also own a fair bit of Finward Bancorp we think they are probably pretty confident of a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 2 warning signs for Finward Bancorp you should be aware of, and 1 of these is a bit concerning.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why this is a must-watch in Nvidia's earnings report
Why this is a must-watch in Nvidia's earnings report

Yahoo

time6 minutes ago

  • Yahoo

Why this is a must-watch in Nvidia's earnings report

Nvidia's (NVDA) upcoming earnings day may boil down to one key question: Will China be part of its outlook? "If NVDA were to include China in its guidance, we believe it would contribute an incremental $2-3 billion in revenue," KeyBanc Capital Markets analyst John Vinh wrote in a new note. Vinh expects strong Q2 results, driven by demand for Nvidia's Blackwell GPUs. But he warned that guidance for Q3 could be conservative, given uncertainty around US export licenses to China. Still, KeyBanc reiterated its Overweight rating and lifted its price target to $215 from $190, pointing to Nvidia's central role in the AI boom and supply-demand dynamics that remain firmly in its favor. Nvidia's near-term growth story looks solid without China. Supply of Nvidia's Blackwell B200 GPU jumped 40% in Q2 and could rise another 20% in Q3, according to Vinh. Simultaneously, shipments of the more advanced Blackwell Ultra (B300) are ramping up, reinforcing Nvidia's dominance in AI chips. KeyBanc raised its full-year shipment forecast for Nvidia's rack-sale AI systems, known as GB200. The firm now expects 30,000 units to ship this year, up from 25,000 previously, citing stronger yields and improved supply-chain execution. For now, KeyBanc assumes Nvidia will exclude China revenue from its guidance. That mirrors the approach of Advanced Micro Devices (AMD), which earlier this month left China out of its outlook amid the same regulatory uncertainty. The Chinese impact on Nvidia is significant. KeyBanc raised its Q2 revenue estimate to $47.1 billion from $45.1 billion, above Wall Street's consensus of $45.7 billion. It raised earnings per share to $1.05 from $0.99, slightly above consensus of $1.00. But with Nvidia agreeing to pay 15% of Chinese chip sales to the US government, plus China's push for domestic AI chips, the company is likely to adopt a more conservative stance on its financial forecast. For Q3, KeyBanc cut its revenue estimates to $50.4 billion from $53.5 billion, versus a consensus of $52.6 billion. EPS was clipped to $1.14 from $1.22, below the Street's consensus of $1.19. Longer term, KeyBanc trimmed fiscal 2026 forecasts on China risks, but boosted 2027 expectations on stronger rack shipments due to accelerating spending by hyperscalers like Amazon (AMZN), Microsoft (MSFT), and Google (GOOG). Wall Street remains bullish. Morgan Stanley recently called Nvidia the most undervalued megacap stock in the market. Its shares are up more than 30% year to date and over 35% in the past 12 months. Francisco Velasquez is a Reporter at Yahoo Finance. He can be reached on LinkedIn and X, or via email at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Rising Phoenix Capital sells mineral package in Barnett Shale, US
Rising Phoenix Capital sells mineral package in Barnett Shale, US

Yahoo

time6 minutes ago

  • Yahoo

Rising Phoenix Capital sells mineral package in Barnett Shale, US

Boutique investment company Rising Phoenix Capital has completed the sale of a significant mineral package in the Barnett Shale, Denton County, Texas, US. The 661.88-net-royalty-acre asset, operated by BKV Barnett, was a component of the Rising Phoenix Royalty Fund III and is known for its high cash flow and development potential. While the industry's attention has largely turned to the Permian Basin, Rising Phoenix Capital has strategically capitalised on assets in less targeted areas like the Barnett Shale. Rising Phoenix Capital CEO and founder Jace Graham said: 'We are active in the Permian, but we also look for opportunities in areas like the Barnett Shale, where competition is lower, pricing can be more favourable, and the right deals can deliver strong, stable returns.' The company acquired the Denton County asset from a commercial land development company, recognising early signs of renewed drilling interest. BKV Barnett's development activities have since confirmed, with two wells completed in June 2023, two last December and three more spudded in March of this year. Jace Graham said: 'This was a classic example of what we look for: strong current cash flow with identifiable upside. 'BKV's activity added value for our fund, and we were able to complete a sale that generated excellent returns for our investors while still leaving some meat on the bone for the buyer to monetise.' The details of the buyer and the sales price remain confidential; however, the transaction is expected to elevate the performance of Rising Phoenix Royalty Fund III towards the higher end of its expected returns. Rising Phoenix Capital's strategy concentrates on acquiring cash-flowing, yield-generating oil and gas mineral assets with stable production and development potential. Graham, who manages a portfolio for Rising Phoenix Capital, oversees around 16,000 net royalty acres in the Barnett Shale. This is part of a broader portfolio that spans various US basins. For investors looking for managed opportunities in the energy sector, Rising Phoenix Capital's La Plata Peak Fund is designed to provide monthly income and capital appreciation by targeting producing mineral assets with development upside across multiple basins. Currently, Rising Phoenix Capital is accepting subscriptions for this fund, offering diversified mineral portfolios with immediate cash flow and long-term growth potential. In a recent expansion of its portfolio, the company purchased mineral interests in the Midland Basin managed by ConocoPhillips. "Rising Phoenix Capital sells mineral package in Barnett Shale, US" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bluesight introduces ShortageCheck to manage drug inventories in hospitals
Bluesight introduces ShortageCheck to manage drug inventories in hospitals

Yahoo

time6 minutes ago

  • Yahoo

Bluesight introduces ShortageCheck to manage drug inventories in hospitals

Hospital intelligence solutions provider Bluesight has launched ShortageCheck technology designed to assist health systems and hospitals in tracking, forecasting and managing drug inventories. ShortageCheck integrates real-time inventory data, predictive analytics, and collaborative planning tools into a comprehensive platform. This innovation is poised to ensure that caregivers and patients have uninterrupted access to essential medications. Monitoring over 20 real-time market signals, encompassing demand spikes and fulfilment delays, ShortageCheck provides coverage across more than 2,500 acute care facilities across the US. It identifies early warning signs of drug shortages, offering up to a 90-day lead time, with an average of 42 days, allowing healthcare institutions to prepare and adapt their inventory management strategies. By assessing levels of inventory, usage rates along with days-on-hand, the platform offers in-depth insights into the potential impact of each shortage. This enables organisations to evaluate risk, prioritise responses and leverage ShortageCheck's communication tools for cross-team coordination and planning. Bluesight CEO and co-founder Kevin MacDonald said: 'Shortage management has been one of, if not the most critical, pain point for our customers over the last six years. When drug shortages hit without warning, it forces teams to scramble for alternatives, and patient care ultimately suffers. 'With improving health system operations as our top priority, the launch of ShortageCheck marks a significant milestone in ensuring customers have the solutions needed to get ahead of shortages before they hit, preserving labour hours and costs during a time when drug costs are rising, staff shortages persist, and medicare reimbursement changes are on the horizon.' ShortageCheck is part of the hospital intelligence solutions suite of Bluesight, which includes CostCheck, KitCheck, 340BCheck, ControlCheck and PrivacyPro. These tools collectively offer hospitals the capability to restock inventory quicker, reduce drug expenditure, streamline audit preparations, pinpoint drug diversion more effectively, and save time in protecting patient privacy. This January, Bluesight expanded its capabilities by acquiring Protenus, a healthcare compliance analytics platform provider. "Bluesight introduces ShortageCheck to manage drug inventories in hospitals" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store